Value of anti-melanoma differentiation-related gene 5 antibody for assessing disease activity and prognosis in patients with dermatomyositis-associated interstitial lung disease

Abstract

Abstract:

Objective:To study the expression level of anti-melanoma differentiation gene 5 antibody (anti-MDA5 antibody) in serum of idiopathic inflammatory myopathy (IIM) patients associated with interstitial lung disease (ILD), and to explore the relationship between anti-MDA5 antibody and clinical characteristics, severity and 6-month mortality of IIM-ILD patients for providing laboratory evidences to delineate new immune intervention pathway.Methods:The expression of anti-MDA5 antibody in serum of 104 patients with IIM or IIM-ILD, including polymyositis 4 cases, dermatomyositis 8 cases, amyopathic dermatomyositis, 7 cases, polymyositis-ILD 17 cases, dermatomyositis-ILD 25 cases, amyopathic dermatomyositis-ILD 43cases, and normal control group was detected by ELISA, and the relationships between anti-MDA5 antibody and lung function [FVC% and DLCO/SB (single breath, carbon monoxide diffusing capacity)], lung structure [HRCT score (high resolution CT score)] and 6-month survival were analyzed.Results:In patients with amyopathic dermatomyositis (ADM), the serum level of anti-MDA5 antibody was higher than that of normal controls, patients with dermatomyositis (DM), IIM not associated with ILD and polymyositis (PM) with ILD(P<0.005). Compared with DM-ILD patients, the serum level of anti-MDA5 antibody in patients with ADM-ILD was increased (P<0.05). There was no correlation between anti-MDA5 antibody level and lung function in patients with IIM (FVC%r=-0.04425P=0.7579, DLCO/SB,r=-0.06839P=0.6335), and was positively correlated with lung structural changes (r=0.3879P=0.0002). The 6-month mortality of IIM patients with positive anti-MDA5 antibody was significantly different from that of anti-MDA5 antibody negative patients (P=0.0002).Conclusions:The anti-MDA5 antibody level detected by ELISA is closely correlated with lung function, severity of lung structural damage and mortality in patients with DM-ILD, especially ADM-ILD.

Key words:Dermatomyositis,Interstitial lung disease,Anti-MDA5 antibody,Clinical features

CLC Number:

R563.13

WANG Juan, WANG Kaiwen, ZHAO Jiangfeng. Value of anti-melanoma differentiation-related gene 5 antibody for assessing disease activity and prognosis in patients with dermatomyositis-associated interstitial lung disease[J]. Journal of Diagnostics Concepts & Practice, 2019, 18(2): 155-159.

Figures/Tables4

参数	IIM(n=19)			IIM-ILD(n=85)
参数	PM（n=4）	DM（n=8）	ADM（n=7）	PM-ILD（n=17）	DM-ILD（n=25）	ADM-ILD（n=43）
年龄 (岁)	58.25±11.59	44.75±22.80	34.14±17.59	53.71±11.33	53.72±8.63	49.26±12.30
女性%	75.00	50.00	85.71	82.35	52.00	72.09
病程(年)	3.03±2.00	0.91±0.89	0.97±1.06	1.42±1.83	1.22±1.51	1.34±1.64
ILD病程 (年)	/	/	/	0.88±1.14	1.03±1.18	1.14±1.57
C反应蛋白 (mg/L)	2.92±0.63	2.74±3.23	3.20±1.43	6.73±7.17	18.01 ± 40.74	11.93±22.61
红细胞沉降率(mm/h)	14.33±11.68	30.20±29.18	17.83±10.13	16.41±13.77	27.71±29.36	28.59±19.94
肌酸激酶 (U/mL)	755.33±835.45	306.20±230.38	55.50±62.29	905.00±1106.49	592.22±1244.29	87.83±133.51
铁蛋白 (ng/mL)	358.03±398.49	487.34±450.09	189.68±198.49	536.19±944.29	938.51±1108.23	1,238.72±1430.43
抗MDA5抗体阳性率 (%)	0 (0.00%)	1 (12.50%)	2 (28.57%)	2 (11.76%)	11 (44.00%)	36 (83.72%)
抗ARS抗体阳性率 (%)	0 (0.00%)	1 (12.50%)	0 (0.00%)	8 (47.06%)	9 (36.00%)	3 (6.98%)
涎液化糖链抗原(U/mL)	741.00±672.02	1,150.75±2019.28	358.14±193.72	1,107.59±2329.15	1,482.60±1787.08	1,146.86±975.08
用力肺活量（%）	92.37±10.68	99.23±13.97	89.40±12.80	68.53±16.05	71.86±24.91	65.51±25.11
一氧化碳扩散功能 (mmol·min^-1·kPa^-1)	72.17±24.22	75.23±21.99	70.10±13.08	43.74±17.18	46.39±17.20	48.48±16.32
高分辨率CT评分（分）	/	/	/	109.46±5.43	132.37±32.73	142.16±41.65

References13

[1]	中华医学会风湿病学分会. 多发性肌炎和皮肌炎诊断及治疗指南[J]. 中华风湿病学杂志, 2010, 14(12):828-831.
[2]	Fathi M, Lundberg IE. Interstitial lung disease in polymyositis and dermatomyositis[J]. Curr Opin Rheumatol, 2005, 17(6):701-706.
[3]	Cottin V, Thivolet-Béjui F, Reynaud-Gaubert M, et al. Interstitial lung disease in amyopathic dermatomyositis, dermatomyositis and polymyositis[J]. Eur Respir J, 2003, 22(2):245-250.
[4]	Kang EH, Lee EB, Shin KC, et al. Interstitial lung disease in patients with polymyositis, dermatomyositis and amyopathic dermatomyositis[J]. Rheumatology (Oxford), 2005, 44(10):1282-1286.
[5]	Ye S, Chen XX, Lu XY, et al. Adult clinically amyopathic dermatomyositis with rapid progressive interstitial lung disease: a retrospective cohort study[J]. Clin Rheumatol, 2007, 26(10):1647-1654.
[6]	Ghirardello A, Zampieri S, Iaccarino L, et al. Myositis specific and myositis associated autoantibodies in idiopathic inflammatory myopathies: a serologic study of 46 patients[J]. Reumatismo, 2005, 57(1):22-28.
[7]	Chen Z, Cao M, Plana MN, et al. Utility of anti-melanoma differentiation-associated gene 5 antibody measurement in identifying patients with dermatomyositis and a high risk for developing rapidly progressive interstitial lung disease: a review of the literature and a meta-analysis[J]. Arthritis Care Res(Hoboken), 2013, 65(8):1316-1324.
[8]	Sontheimer RD, Miyagawa S. Potentially fatal interstitial lung disease can occur in clinically amyopathic dermatomyositis[J]. J Am Acad Dermatol, 2003, 48(5):797-798.
[9]	Ikezoe J, Johkoh T, Kohno N, et al. High-resolution CT findings of lung disease in patients with polymyositis and dermatomyositis[J]. J Thorac Imaging, 1996, 11(4):250-259.
[10]	Sato S, Hoshino K, Satoh T, et al. RNA helicase encoded by melanoma differentiation-associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis: Association with rapidly progressive interstitial lung disease[J]. Arthritis Rheum, 2009, 60(7):2193-200.
[11]	Mukae H, Ishimoto H, Sakamoto N, et al. Clinical diffe-rences between interstitial lung disease associated with clinically amyopathic dermatomyositis and classic dermatomyositis[J]. Chest, 2009, 136(5):1341-1347.
[12]	Sato S, Murakami A, Kuwajima A, et al. Clinical Utility of an Enzyme-Linked Immunosorbent Assay for Detecting Anti-Melanoma Differentiation-Associated Gene 5 Autoantibodies[J]. PLoS One, 2016, 11(4):e0154285.
[13]	Kochi Y, Kamatani Y, Kondo Y, et al. Splicing variant of WDFY4 augments MDA5 signalling and the risk of clinically amyopathic dermatomyositis[J]. Ann Rheum Dis, 2018, 77(4):602-611.